Showing 2041-2050 of 5771 results for "".
- Ocular Therapeutix Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patients-dosed-in-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease/2478343/Ocular Therapeutix announced that it has dosed the first patients in its hase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease. “Having successfully completed the phase 1 study, we are excited to have recently begun dosing patients in
- Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 Eye Drop for Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-new-drug-application-for-ar-15512-eye-drop-for-dry-eye-disease/2478340/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug application (IND) for AR-15512 (TRPM8 agonist) eye drop for dry eye and it is now in effect, allowing Aerie to in
- Haag-Streit UK Announces Launch of the MR Q and MR Q Supine Laser Systems in the UKhttps://modernod.com/news/haag-streit-uk-announces-launch-of-the-mr-q-and-mr-q-supine-laser-systems-in-the-uk/2478337/Haag-Streit UK (HS-UK) has announced the launch of the Meridian MR Q and MR Q supine YAG lasers in the UK. The MR Q is a fully-integrated YAG laser, which features the latest technology for posterior capsulotomy, pupillary membranectomy, and iridotomy. The laser boasts outstanding u
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- Visus Therapeutics Launches and Announces Clinical Development Program for Novel Presbyopia Eye Drophttps://modernod.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/Visus Therapeutics announced its launch and clinical development program for a novel eye drop designed to restore the loss of near vision associated with presbyopia. Visus’ lead product candidate is Brimochol, a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and
- Bausch Health Announces Vyzulta Now Approved in Seven Countries; Expanded Coverage in Canadahttps://modernod.com/news/bausch-health-announces-vyzulta-now-approved-in-seven-countries-expanded-coverage-in-canada/2478323/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval in Ukraine, bringing the total number of countries where Vyzulta is approved to market to seven. These countries include
- Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/Fight for Sight and Prevent Blindness announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elam’s study, “Engag
- Aerie Pharmaceuticals Announces Interim 90-Day Topline Data From Its 6-Month Mercury 3 Clinical Trial in Europehttps://modernod.com/news/aerie-pharmaceuticals-announces-interim-90-day-topline-data-from-its-6-month-mercury-3-clinical-trial-in-europe/2478321/Aerie Pharmaceuticals announced successful interim 90-day topline data from its 6-month phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda to Ganfort, according to a company news release. Roclanda is marketed in the United States as Rocklatan (netarsudil and latanopro
- Alsanza Announces Launch of Alsafit Fourier Optic IOLhttps://modernod.com/news/alsanza-announces-launch-of-alsafit-fourier-optic-iol/2478312/Alsanza announced the launch of the Alsafit Fourier Optic presbyopia correcting IOL. The optic structure of the Fourier Optic is free of sharp edges on the optic surface and features the first reverse apodized optic that benefits dynamic light distribution, according to a company news rele
- Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edemahttps://modernod.com/news/emmecell-announces-fda-acceptance-of-ind-application-for-eo2002-in-corneal-edema/2478310/Emmetrope Ophthalmics announced that the FDA has accepted the investigational new drug application (IND) for EO2002, its lead candidate for the treatment of corneal edema. The active IND enables Emmecell to initiate a phase 1 clinical trial designed to assess the tolerability, safety, and efficac